Clinical trials: Bronchogenic Cancer
Non-small Cell Lung Cancer, Malignant Pleural Effusion
Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
Malignant pleural or pericardial effusion is common in lung cancer, and intrapleural drugs injection is important in the treatment.
- Trial name
- NCT02054052
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Haihong Yang, MD, Pricipal investigator
Non-Small Cell Lung Cancer
A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47
The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in patients with non-squamous non-small cell lung cancer when given as a monotherapy.
- Trial name
- NCT02340208
- Testing
- L-DOS47
- Where
- 5 sites in Poland
- Volunteers
- 76 people
- Sponsor
- Helix BioPharma Corporation
Lung Cancer Metastatic
Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC
This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2（VEGFR）、FGFR（fibroblast growth factor receptor）, platelet-derived growth factor…
- Trial name
- NCT03706287
- Testing
- anlotinib 8mg + AP/PC, anlotinib 10mg + AP/PC, anlotinib 12mg + AP/PC
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Extensive-Stage Small Cell Lung Cancer
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel work in treating participants with small cell lung cancer after failing to platinum-etoposide chemotherapy.
- Trial name
- NCT04056949
- Testing
- Paclitaxel/Albumin-Bound Paclitaxel, IBI308
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Junling Li
Lung Cancer, Metastatic Cancer
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
RATIONALE: Studying samples of pleural fluid in the laboratory from patients with lung cancer may help doctors identify early lung cancer cells. It may also help the study of lung cancer in the future.
- Trial name
- NCT00897143
- Testing
- microarray analysis, mutation analysis, flow cytometry
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
Non-small Cell Lung Cancer
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR)…
- Trial name
- RECEL (NCT01714908)
- Testing
- Erlotinib w Concurrent Radiotherapy, etoposide/cis-platin (EP) w Concurrent Radiotherapy
- Where
- 19 sites in China
- Volunteers
- 100 people
- Sponsor
- Jinming Yu
Non-small Cell Lung Cancer
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients with advanced non-squamous non-small cell lung…
- Trial name
- NCT02590965
- Testing
- Fruquintinib
- Where
- 12 sites in China
- Volunteers
- 91 people
- Sponsor
- Hutchison Medipharma Limited
Stage IV Non-small Cell Lung Cancer
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
- Trial name
- NCT01310244
- Testing
- Belinostat, Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC )
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.
- Conditions
- Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma
- Trial name
- NCT07914764
- Testing
- Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Non Small Cell Lung Cancer
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation
An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 （anti-PD-1 monoclonal antibody）in advanced NSCLC patients…
- Trial name
- NCT05641493
- Testing
- HLX208+HLX10
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Henlius Biotech
Lung Cancer, Non-small Cell
Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC
Lung cancer (LC) remains a leading cause of death among cancers worldwide. Though radiotherapy is one of the most frequently used treatments, it increases side-effects (pain, fatigue) and inflammation, possibly leading to further…
- Trial name
- NCT03553485
- Testing
- Transcutaneous vagus nerve stimulation, Radiotherapy
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- Vrije Universiteit Brussel
Lung Cancer, Non-Small Cell Lung Cancer
Molecular Profiling Project
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.
- Trial name
- NCT04025515
- Where
- 10 sites in Brunei, Hong Kong and 4 more
- Volunteers
- 500 people
- Sponsor
- National Cancer Centre, Singapore
NSCLC Stage IIIA/B
Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)
Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT)
- Trial name
- NCT02118415
- Testing
- Hsp70-peptide TKD/IL-2 activated, autologous NK cells
- Where
- Germany
- Volunteers
- 13 people
- Sponsor
- Technical University of Munich
Non-Small Cell Lung Cancer
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to durvalumab will improve the results of the treatment for non-small-cell lung cancer.
- Trial name
- NCT02673814
- Testing
- durvalumab, bavituximab
- Sponsor
- Peregrine Pharmaceuticals
Health Status Unknown, Lung Cancer
Liverpool Lung Project: Risk Factors and Genetic Markers in Healthy Participants and Patients With Lung Cancer
RATIONALE: Environmental exposure and genetic predisposition may affect the risk of developing cancer later in life. Learning about genetic markers and the long-term effects of environmental exposure may help the study of lung…
- Trial name
- NCT00503958
- Testing
- DNA methylation analysis, DNA stability analysis, gene expression analysis
- Where
- 5 sites in United Kingdom
- Volunteers
- 8,300 people, healthy volunteers welcome
- Sponsor
- University of Liverpool Cancer Research Centre
Small Cell Lung Cancer
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal…
- Trial name
- NCT06500026
- Testing
- BL-B01D1, Topotecan
- Where
- China
- Volunteers
- 722 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Lung Cancer, Non-Small Cell, Lung Cancer, Small Cell
The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
The goal of this prospective, multi-centre, randomised controlled clinical study is to evaluate the diagnostic efficacy and safety of nCLE guided lung biopsy in patients with for peripheral lung nodules under the assistance of…
- Trial name
- NCT06739421
- Testing
- nCLE-NB-rEBUS-forcep biopsy, nCLE-NB-rEBUS-TBCB, NB-rEBUS-forcep biopsy
- Where
- China
- Volunteers
- 1,040 people
- Sponsor
- China-Japan Friendship Hospital
Non-Small Cell Lung Cancer, NSCLC
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
The purpose of this study is to determine whether the combination of MM-121 plus docetaxel is more effective than docetaxel alone in regards to PFS in patients with heregulin-positive NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
- Trial name
- SHERLOC (NCT02387216)
- Testing
- MM-121, Docetaxel
- Where
- 35 sites in United States, Canada and 4 more
- Volunteers
- 153 people
- Sponsor
- Elevation Oncology
Non-Small Cell Lung Cancer
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung…
- Trial name
- NCT03594747
- Testing
- Tislelizumab, Paclitaxel, Nab-paclitaxel
- Where
- 43 sites in China
- Volunteers
- 360 people
- Sponsor
- BeiGene
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.